Absolute CD19, CD20, dual CD19/CD5, and total lymphocyte (ALC) counts in a cohort of patients (n = 322) with MBL with a typical “CLL phenotype”
| Absolute count ×109/L . | CD19 . | CD20 . | CD19/CD5 . | Lymphocytes (ALC) . |
|---|---|---|---|---|
| 0.0-0.99 | 44 (13.7%) | 45 (14.0%) | 62 (19.2%) | 6 (1.9%) |
| 1.0-1.99 | 57 (17.7%) | 64 (19.9%) | 70 (21.7%) | 17 (5.3%) |
| 2.0-2.99 | 69 (21.4%) | 73 (22.6%) | 71 (22.1%) | 16 (5.0%) |
| 3.0-3.99 | 84 (26.1%) | 86 (26.7%) | 82 (25.5%) | 38 (11.8%) |
| 4.0-4.99 | 68 (21.1%) | 48 (14.9%) | 35 (10.9%) | 79 (24.5%) |
| 5.0-5.99 | 6 (1.9%) | 2 (0.6%) | 70 (21.7%) | |
| 6.0-6.99 | 69 (21.4%) | |||
| 7.0-7.99 | 20 (6.2%) | |||
| 8.0-8.99 | 5 (1.6%) | |||
| 9.0-9.99 | 1 (0.3%) | |||
| 10 + | 1 (0.3%) |
| Absolute count ×109/L . | CD19 . | CD20 . | CD19/CD5 . | Lymphocytes (ALC) . |
|---|---|---|---|---|
| 0.0-0.99 | 44 (13.7%) | 45 (14.0%) | 62 (19.2%) | 6 (1.9%) |
| 1.0-1.99 | 57 (17.7%) | 64 (19.9%) | 70 (21.7%) | 17 (5.3%) |
| 2.0-2.99 | 69 (21.4%) | 73 (22.6%) | 71 (22.1%) | 16 (5.0%) |
| 3.0-3.99 | 84 (26.1%) | 86 (26.7%) | 82 (25.5%) | 38 (11.8%) |
| 4.0-4.99 | 68 (21.1%) | 48 (14.9%) | 35 (10.9%) | 79 (24.5%) |
| 5.0-5.99 | 6 (1.9%) | 2 (0.6%) | 70 (21.7%) | |
| 6.0-6.99 | 69 (21.4%) | |||
| 7.0-7.99 | 20 (6.2%) | |||
| 8.0-8.99 | 5 (1.6%) | |||
| 9.0-9.99 | 1 (0.3%) | |||
| 10 + | 1 (0.3%) |
Data show number of patients and percentage (in parentheses).